PDF(Pubmed)
Abstract：
The MET receptor is one of the main drivers of \'invasive growth\', a multifaceted biological response essential during embryonic development and tissue repair that is usurped by cancer cells to induce and sustain the malignant phenotype. MET stands out as one of the most important oncogenes activated in cancer and its inhibition has been explored since the initial era of cancer-targeted therapy. Different approaches have been developed to hamper MET signaling and/or reduce MET (over)expression as a hallmark of transformation. Considering the great interest gained by cancer immunotherapy, this review evaluates the opportunity of targeting MET within therapeutic approaches based on the exploitation of immune functions, either in those cases where MET impairment is crucial to induce an effective response (i.e., when MET is the driver of the malignancy), or when blocking MET represents a way for potentiating the treatment (i.e., when MET is an adjuvant of tumor fitness).
摘要：
MET受体是“侵入性生长”的主要驱动因素之一，在胚胎发育和组织修复过程中必不可少的多方面生物学反应，被癌细胞篡夺以诱导和维持恶性表型。MET是癌症中激活的最重要的癌基因之一，自癌症靶向治疗的最初时代以来，人们一直在探索其抑制作用。已经开发了不同的方法来阻碍MET信号传导和/或减少作为转化标志的MET(过)表达。考虑到癌症免疫疗法获得的极大兴趣，这篇综述评估了基于免疫功能开发的治疗方法中靶向MET的机会，在MET损伤对诱导有效反应至关重要的情况下(即，当MET是恶性肿瘤的驱动因素时)，或者当阻断MET代表一种增强治疗的方法(即，当MET是肿瘤适应性的佐剂时)。
